key: cord-0994125-uge1lpaq
authors: Hilser, James R.; Han, Yi; Biswas, Subarna; Gukasyan, Janet; Cai, Zhiheng; Zhu, Ruowei; Tang, W.H. Wilson; Deb, Arjun; Lusis, Aldons J.; Hartiala, Jaana A.; Allayee, Hooman
title: Association of serum HDL cholesterol and apolipoprotein A1 levels with risk of severe SARS-CoV-2 infection
date: 2021-03-02
journal: J Lipid Res
DOI: 10.1016/j.jlr.2021.100061
sha: 510aafa2bbbacc1cabb55f9838b8098cb93b6191
doc_id: 994125
cord_uid: uge1lpaq

Individuals with features of metabolic syndrome are particularly susceptible to SARS-CoV-2, a novel coronavirus associated with the severe respiratory disease COVID-19. Despite considerable attention dedicated to COVID-19, the link between metabolic syndrome and SARS-CoV-2 infection remains unclear. Using data from the UK Biobank, we investigated the relationship between severity of COVID-19 and metabolic syndrome-related serum biomarkers measured prior to SARS-CoV-2 infection. Logistic regression analyses were used to test biomarker levels and biomarker-associated genetic variants with SARS-CoV-2-related outcomes. Among SARS-CoV-2-positive cases and negative controls, a 10mg/dL increase in serum high-density lipoprotein (HDL) cholesterol or apolipoprotein A1 (ApoA1) levels was associated with ∼10% reduced risk of SARS-CoV-2 infection, after adjustment for age, sex, obesity, hypertension, type 2 diabetes, and coronary artery disease. Evaluation of known genetic variants for HDL cholesterol revealed that individuals homozygous for ApoE4 alleles had ∼2-3-fold higher risk of SARS-CoV-2 infection or mortality from COVID-19 compared to ApoE3 homozygotes, even after adjustment for HDL cholesterol levels. However, cumulative effects of all evaluated HDL cholesterol-raising alleles and Mendelian randomization analyses did not reveal association of genetically higher HDL cholesterol levels with decreased risk of SARS-CoV-2 infection. These results implicate serum HDL cholesterol and ApoA1 levels measured prior to SAR-CoV-2 exposure as clinical risk factors for severe COVID-19 infection but do not provide evidence that genetically elevated HDL cholesterol levels are associated with SAR-CoV-2 infection.

In December 2019, a novel virus originating from Wuhan, China was identified and associated with a rare and, in some cases, fatal form of pneumonia (1) . Genetic analyses revealed the infectious agent to be a member of the enveloped single-stranded RNA family of coronaviruses, which were also the causes of previous severe acute respiratory syndrome shown that men and individuals with pre-existing metabolic conditions, such as obesity, hypertension, type 2 diabetes, chronic kidney disease, and coronary artery disease (CAD), are more prone to developing COVID-19, the severe viral pneumonia illness associated with SARS-CoV-2 infection (7) (8) (9) (10) (11) (12) (13) . However, the underlying pathophysiological mechanisms for these associations are not well understood.

In addition to comorbidities, studies have also sought to identify clinical biomarkers that are associated with the severity of COVID-19 and its progression. For example, circulating levels of lipids and acute phase inflammatory proteins have been associated with poor outcomes and predictive of death among COVID-19 patients (13) (14) (15) . However, these associations were based on measurements obtained at the time of symptomatic presentation or during the course of SARS-CoV-2 infection (16) (17) (18) . Thus, such studies do not necessarily provide definitive evidence that the biomarkers analyzed play a causal role in influencing COVID-19 outcomes since infection itself can alter the levels of lipids and acute phase inflammatory proteins (19) .

In the present study, we sought to identify metabolic disease-related clinical biomarkers using measurements made prior to the current COVID-19 outbreak and evaluate their genetic determinants for association with SARS-CoV-2 infection. We report associations between highdensity lipoprotein (HDL) cholesterol and apolipoprotein A1 (ApoA1) levels with risk of severe SARS-CoV-2 infection. These results provide evidence for the concept that HDL metabolism may play a role in susceptibility to severe manifestations and adverse outcomes of SARS-CoV-2 infection.

J o u r n a l P r e -p r o o f Materials and Methods 1 2 Study Population. Between 2006-2010, the UK Biobank recruited a total of 503,325 3 participants who were 40-69 years of age and registered with a general practitioner of the UK 4 National Health Service (20) . At enrollment, extensive data on demographics, ethnicity, 5 education, and disease-related outcomes were obtained through questionnaires or health records. 6

Baseline blood samples were also collected for measurement of serum biomarkers that are either 7 established disease risk factors or routinely measured as part of clinical evaluations. Subsequent 8 to the COVID-19 pandemic in Spring 2020, the UK Biobank began releasing the results of PCR-9 based tests for SARS-CoV-2 infection among its participants (Data-Field 40100). Initially, 10 testing for SARS-CoV-2 infection in the UK was primarily restricted to symptomatic subjects 11 admitted to one of the National Health Service hospitals 12 J o u r n a l P r e -p r o o f predisposing risk factors, we also defined a matched dataset by matching hospital-based controls 1 to cases at a ratio of 2:1 based on age, sex, obesity, hypertension, type 2 diabetes, and coronary 2 artery disease (CAD) using a previously described algorithm (21) . These criteria define a subset 3 of 719 cases and 1,438 matched hospital-based controls with complete matching variables that 4

were available for analysis. Since there would be insufficient numbers of controls of other 5 ethnicities to allow complete matching to non-white European ancestry cases, we only included 6 subjects of self-reported white European ancestry in these analyses. All UK Biobank 7 participants provided informed consent. The study protocol was approved by the North West Mann-Whitney U tests for continuous traits, respectively. Differences in clinical biomarkers 16 measured at the time of enrollment between cases and controls were evaluated using Mann-17 Whitney U tests. Spearman's correlation tests were used to assess relationships between 18 biomarkers. HDL cholesterol, ApoA1, and triglyceride levels were further evaluated for 19 association with SAR-CoV-2 infection using logistic regression. For analyses with cases and 20 unmatched hospital-based controls, the base model (model 1) included age, sex, the first 10 21 principal components (PC1-10), obesity, hypertension, type 2 diabetes, and CAD as covariates. infection among cases and unmatched hospital-based controls as well as with mortality among 1 cases only, with adjustment for age, sex, obesity, hypertension, type 2 diabetes, CAD, BMI, 2 education, smoking, PC1-10, and genotyping array. Conditional logistic regression was used to 3 test association of the three GRS's with SARS-CoV-2 infection among cases and matched 4 hospital-based controls with adjustment for BMI, education, smoking, PC1-10, and genotyping 5 array. GRS analyses were carried out with SAS 9.4 (SAS Institute, Inc, Cary NC). (2SMR) was performed with HDL cholesterol-associated SNPs as instrumental variables using 10 several methods (MR Egger, weighted median, and inverse variance weighted). For these 11 analyses, the association between HDL cholesterol-associated SNPs and HDL cholesterol levels 12 in ~400,000 UK Biobank subjects of self-reported white European ancestry were considered as 13 the exposure variable. The association between HDL cholesterol-related variants and risk of 14 SARS-CoV-2 infection in the unmatched (n~4,000) or matched (n~2,000) hospital case-control 15 datasets from the UK Biobank was considered as the outcome. These analyses used all HDL 16 cholesterol-associated variants (tier 1) that were not palindromic and for which association 17 results for HDL cholesterol levels and risk of SARS-CoV-2 infection were available. To 18 minimize horizontal pleiotropy, we also carried out the same MR analyses with a subset of 35 19 HDL cholesterol-associated variants (tier 2) that exhibited association with HDL cholesterol, but 20 not LDL cholesterol or triglyceride, levels at the genome-wide significance threshold (P=5.0x10 -21 cholesterol, LDL cholesterol, and triglycerides) simultaneously on SARS-CoV-2 infection. 1 MVMR analyses were carried out with both tier 1 and tier 2 SNPs. Lastly, MR analyses were 2 also carried out using previously published genetic effect sizes for HDL cholesterol levels and 3 risk of severe SARS-CoV-2 infection (24, 27) . All MR analyses were carried out in R (v3.6.2) 4 using the "TwoSampleMR" (28) and "MVMR" packages (29). 5

Clinical Characteristics of SARS-CoV-2 Cases and Controls. Subsequent to the COVID- 19 3 pandemic in Spring 2020, the UK Biobank began releasing the results of PCR-based tests for 4 SARS-CoV-2 infection among its participants. Based on information related to SARS-CoV-2 5 infection status and other available data on demographics, clinical characteristics, serum 6 biomarkers, and genetic variants, we defined a group of hospital-based cases and controls as well 7 as a matched case-control dataset using a subset of these subjects (Figure 1 ). As a validation 8 step, we first compared cases and unmatched controls with respect to various co-morbidities that 9

have been reported to be associated with the severity of and poor outcomes among COVID- 19 10 patients. As shown in Table 1 , SARS-CoV-2-positive cases were more likely to be male, obese, 11

and have type 2 diabetes, elevated diastolic blood pressure, and higher body mass index (BMI) 12 than unmatched hospital-based controls. These observations are largely consistent with 13 previously reported characteristics of COVID-19 patients in other populations and further 14 support the concept that metabolic disease increases susceptibility to developing severe 15 symptoms of SARS-CoV-2 infection. As expected, there were no differences in clinical 16 variables between cases and matched hospital-based controls ( Table 1) . 17 18

We next compared cases and controls for differences in serum levels of nine previously 20 measured circulating metabolic biomarkers that are routinely evaluated clinically or are 21 established risk factors for obesity, type 2 diabetes, hypertension, and CAD. As show in Table  22 2, cases had significantly lower serum HDL cholesterol (P=3.0x10 -11 ) and ApoA1 (P=5.7x10 -10 ) 23 levels compared to unmatched hospital-based controls. SARS-CoV-2-infected cases also had 24 higher triglycerides, which is not unexpected given the well-known inverse relationship with 1 HDL cholesterol (and ApoA1) levels, and modestly higher HbA1c ( Table 2 ). In the matched 2 case-control dataset, directionally consistent differences were also observed with HDL 3 cholesterol, ApoA1 level, and triglyceride levels ( Table 2) . 4 We next focused on HDL cholesterol, ApoA1, and triglycerides since these biomarkers 5 are metabolically related, have been shown to be relatively stable during adulthood (30) , and 6

were associated with SARS-CoV-2 infection, even after a conservative Bonferroni-adjusted P-7 value for testing nine biomarkers (P=0.05/9=0.006) ( Table 2 ). In comparisons between cases 8 and unmatched hospital-based controls, a 10mg/dL or one interquartile range (IQR) increase in 9 serum HDL cholesterol levels was associated with significantly (P=4.0x10 -04 ) reduced risk of 10 SARS-CoV-2 infection (OR=0.90, 95% CI 0.85-0.95 or OR=0.82, 95% CI 0.73-0.91, 11 respectively) ( Table 3 ). The effect sizes of these protective associations were similar and only 12 slightly decreased in significance after further adjustment for BMI, education, and smoking 13 ( Table 3 and Figure 2 ). Similar associations were observed between high ApoA1 levels and 14 reduced risk of SARS-CoV-2 infection ( Table 3 and Figure 2 ). Comparisons among cases and 15 matched hospital-based controls also yielded equivalent protective associations with HDL 16 cholesterol and ApoA1 levels ( Table 3 and Figure 2 ). However, association of serum 17 triglyceride levels with SARS-CoV-2 infection only remained significant in the matched case-18 control dataset in the fully adjusted model ( Table 3 and Figure 2 ). In addition, the associations 19 of HDL cholesterol, ApoA1, and triglyceride levels with SARS-CoV-2 infection were not driven 20 by cases whose cause of death was due to COVID-19 since exclusion of these subjects yielded 21 associations that were similar in magnitude and significance to those that included all cases 22 (Table S1) . Taken together, these results indicate that elevated HDL cholesterol and ApoA1 23 levels based on measurements that were made prior to SARS-CoV-2 exposure are inversely 1 associated with risk of severe SARS-CoV-2 infection among subjects from the UK Biobank. Table S2) . 13 Consistent with previous studies (24), many of these variants were also associated with serum 14 triglyceride and/or LDL cholesterol levels, although the significance of the association signals 15 were nearly all attenuated compared to HDL cholesterol levels ( Table S2) . We next tested the 16 155 HDL cholesterol variants individually for association with SARS-CoV-2 infection (Table  17 S2). Nine variants yielded P<0.05 in comparisons between cases and unmatched and/or matched 18 hospital-based controls, although none would be considered significant at a Bonferroni-corrected 19 threshold (Table S3) . 20

Of the variants associated with SARS-CoV-2 infection in either case-control dataset, 21 rs429358 yielded the strongest association among unmatched cases and control (P=4.6x10 -4 ) 22 (Table 3) and was one of the most significantly associated variants with HDL cholesterol levels 23 (P=6.9x10 -142 ) ( Table 2) . Rs429358 is a missense variant in APOE and used in combination 1 with another amino acid substitution (rs7412) to define three common alleles of ApoE (E2, E3, 2 E4). ApoE2 and ApoE4 alleles are known to increase lipid levels and ApoE4 is further 3 recognized as the strongest known genetic risk factor for Alzheimer's disease (31, 32) . Recent 4 analyses have also shown that homozygosity for ApoE4 was associated with significantly higher 5 risk of SARS-CoV-2 infection as well as mortality from COVID-19, even after exclusion of 6 subjects with potential confounding comorbidities, such as dementia, hypertension, type 2 7 diabetes, or CAD (33, 34) . Based on these observations, we evaluated whether previously 8 reported associations between E4/E4 genotype and SARS-CoV-2-related outcomes could be due 9

to effects on HDL cholesterol levels. Consistent with previous observations (33, 34), ApoE4 10 homozygotes had 2-3 fold higher risk of SARS-CoV-2-related outcomes compared to 11

ApoE3/ApoE3 ( with dementia or Alzheimer's disease also yielded directionally consistent, but slightly 17 attenuated, association of ApoE4/ApoE4 genotype with SARS-CoV-2-related outcomes after 18 adjustment for HDL cholesterol levels ( Table S4) cholesterol levels in both cases control datasets. We next tested the unweighted and weighted 7 GRS's for association with SARS-CoV-2 infection or mortality due to COVID-19. As shown in 8 Table S5 , there was no evidence for association of the unweighted or weighted HDL cholesterol 9 GRS's with either of these outcomes. Evaluation of cumulative genetic burden using previously 10 published effect sizes for the 155 SNPs (24) also did not provide evidence for association of a 11

weighted HDL cholesterol GRS with SARS-CoV-2 infection (Table S5) . We also used 12

Mendelian randomization (MR) to evaluate whether genetically increased HDL cholesterol 13 levels were causally associated with SARS-CoV-2-related outcomes. These analyses, which 14 included Two-sample MR (2SMR) and a multivariate approach (MVMR) to account for the 15 pleiotropic association of HDL cholesterol variants with other lipid traits, did not yield evidence 16 that genetically elevated HDL cholesterol levels were associated with decreased risk of SARS-17

CoV-2 infection or mortality due to COVID-19 (Table S6) . MR analyses carried out with 18 previously published effect sizes for HDL cholesterol and risk of severe SARS-CoV-2 infection 19 (24, 27) yielded similar results (Table S6) . 20

In the present study, we sought to identify circulating metabolic biomarkers that were 2 associated with risk of SARS-CoV-2 infection and its adverse outcomes using measurements 3 obtained at the time of enrollment into the UK Biobank but in the context of the current COVID-4 19 pandemic. Of the biomarkers evaluated, protective associations were observed between 5 SARS-CoV-2 infection and high levels of HDL cholesterol or ApoA1, particularly among 6 individuals with the highest levels that were one IQR (~20mg/dL) above the median in whom 7 risk was reduced by ~20%. Importantly, the effect sizes of the protective associations observed 8 between HDL cholesterol or ApoA1 levels and SARS-CoV-2 infection among cases and 9 matched controls were nearly identical to those obtained in analyses using unmatched controls. 10

These results suggest that the associations observed with HDL cholesterol or Apo1 are not likely 11 confounded by pre-existing conditions known to increase susceptibility to COVID-19, such as 12 obesity and type 2 diabetes, since these factors were used as matching variables. In this regard, it 13 is noteworthy that a recent study demonstrated the association of genetically higher BMI and and SARS-CoV-2 infection. However, we did not observe evidence that genetically higher HDL 1 cholesterol levels were associated with SARS-CoV-2 infection. By comparison, a recently 2 published analysis with >400,000 subjects did provide evidence for a causal relationship between 3 HDL cholesterol levels and risk of non-COVID-19-related infectious hospitalizations (51), 4 although the protective genetic associations in that study were very modest (~4% reduced risk) 5 compared to the ~40% decreased risk observed clinically with HDL cholesterol levels. Another 6 consideration is that nearly all previously identified genetic variants for HDL cholesterol levels 7 have, to some degree, pleiotropic associations with other lipid or metabolic traits (24) . This may 8 be particularly relevant for the ApoE variants and isoforms we tested, which have effects on 9 multiple lipid fractions and may thus not be suitable instruments for inferring causality about the 10 role of HDL in SARS-CoV-2 infection. As discussed recently, such horizontal pleiotropy may 11 lead to false positive causal associations but can also decrease the power for detecting true 12 positive associations through the introduction of noise (52) . Interestingly, these potential 13 limitations were recently addressed with respect to HDL cholesterol as a causal biomarker of 14 CAD (53). By using MVMR analysis to account for pleiotropy and CAD case-control datasets 15 that had ~5-fold larger sample sizes compared to those used in previous the studies (54), these 16 authors provided evidence for HDL cholesterol levels being independently associated with CAD 17 through locus-and mechanism-specific causal effects. However, despite using a similar 18 approach in our study, the sample sizes in our MR analyses likely did not provide sufficient 19 power to detect associations between genetically increased HDL cholesterol levels and SARS-20

CoV-2 infection. Thus, we cannot rule out the presence of a causal association between elevated 21 HDL cholesterol levels and risk of COVID-19 based on the datasets used in the present study, 22

which will need to be addressed in larger studies. 23

As part of our genetic analyses, we also evaluated ApoE4 alleles for associations with 1 SARS-CoV-2 outcomes based on recent analyses in the UK Biobank (33, 34) . Although ApoE 2 is found on certain HDL subfractions where it facilitates reverse cholesterol transport, our results 3 suggest that ApoE4 affects susceptibility to severe SARS-CoV-2 infection and mortality from 4 COVID-19 independently of HDL cholesterol levels. This concept is supported by previous 5 studies showing that ApoE has other biological functions that could be relevant to SARS-CoV-2 6 infection (55). For example, ApoE has been shown to prevent infection of various viruses, 7 similar to HDL and ApoA1 (56), with ApoE4 having less effective antiviral activity compared to 8

ApoE3 (57) . ApoE can also decrease coagulation by binding to heparin sulfate proteoglycans 9 that are expressed on endothelial cells (50) . Thus, the similarity of ApoE's functional properties 10 to those of HDL also provide plausible biological mechanisms for the genetic associations we 11 observe between ApoE4 and SARS-CoV-2 infection outcomes. Lastly, we did not independently replicate the associations of HDL cholesterol and ApoA1 levels 10

and APOE genotype with SARS-CoV-2 outcomes, which will need to be addressed in additional 

The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper. A study was designed using data made available by the UK Biobank where cases were defined as symptomatic subjects who tested positive for SARS-CoV-2 infection in a hospital setting or whose cause of death was attributed to COVID-19 (green box). Unmatched controls were defined as subjects who tested negative for SARS-CoV-2 infection in inpatient or outpatient hospital settings. A subset of these subjects was used for a dataset where controls were matched to cases at a ratio of 2:1 based on complete data for age, sex, obesity, hypertension, type 2 diabetes, and CAD (gray box). Comparisons of differences in nine metabolic disease-related biomarker levels between cases and controls (yellow box) were followed by logistic regression analyses with HDL cholesterol, ApoA1, and triglyceride levels (pink box). Previously identified genetic variants associated with HDL cholesterol levels were then evaluated for association with risk of SARS-CoV-2 infection or mortality from COVID-19 using various analytical strategies (blue box). J o u r n a l P r e -p r o o f Conditional logistic regression analysis: Model 1 was only adjusted for PC1-10 and did not include any of the matching variables (age, sex, obesity, hypertension, type 2 diabetes, and CAD). Model 2 was adjusted for PC1-10, BMI, education, and smoking. Data are shown as odds ratios (OR) and 95% confidence intervals (CI). a Logistic regression analysis: Model 1 was adjusted for age, sex, PC1-10, obesity, hypertension, type 2 diabetes, CAD, BMI, education, smoking, and genotyping array. Model 2 was adjusted for the same variables as model 1 with additional adjustment for serum HDL cholesterol levels.

b Conditional logistic regression analysis: Model 1 was adjusted for PC1-10, BMI, education, smoking, and genotyping array. Model 2 was adjusted for the same variables as model 1 with additional adjustment for serum HDL cholesterol levels. c P-values are for comparisons between E4/E4 vs. E3/E3 groups.

A novel coronavirus from patients with pneumonia in China

Identification of a novel coronavirus in patients with severe acute respiratory syndrome

A novel coronavirus associated with severe acute respiratory syndrome

People's Republic of China

Isolation of a novel coronavirus from a man with pneumonia in Saudi Arabia

An interactive web-based dashboard to track COVID-19 in real time

Endocrine and metabolic link to coronavirus infection

Clinical characteristics of 145 patients with corona virus disease 2019 (COVID-19

Gender Differences in Patients With COVID-19: Focus on Severity and Mortality

and Latin American Network of Coronavirus Disease Research. 2020. Clinical, laboratory and imaging features of COVID-19: a systematic review and meta-analysis

Kidney disease is associated with in-hospital death of patients with COVID-19

Factors associated with COVID-19-related death using OpenSAFELY

Clinical characteristics of 3,062 COVID-19 patients: a meta-analysis

Medical Treatment Expert Group for. 2020. Clinical characteristics of coronavirus disease 2019 in China

Clinical characteristics of 140 patients infected with SARS-CoV-2 in Wuhan

Hypolipidemia is associated with the severity of COVID-19

Declined serum high density lipoprotein cholesterol is associated with the severity of COVID-19 infection

Metabolic disturbances and inflammatory dysfunction predict severity of coronavirus disease 2019 (COVID-19): a retrospective study

Effects of infection and inflammation on lipid and lipoprotein metabolism: mechanisms and consequences to the host

The UK Biobank resource with deep phenotyping and genomic data

Matching Cases and Controls Using SAS® Software

A summary of the effects of antihypertensive medications on measured blood pressure

Genome-wide analysis highlights contribution of immune system pathways to the genetic architecture of asthma

Genetics of blood lipids among ~300,000 multi-ethnic participants of the Million Veteran Program

On Jim Watson's APOE status: genetic information is hard to hide

Second-generation PLINK: rising to the challenge of larger and richer datasets

The MR-Base platform supports systematic causal inference across the human phenome

An examination of multivariable Mendelian randomization in the single-sample and two-sample summary data settings

Trajectories of blood lipid concentrations over the adult life course and risk of cardiovascular disease and all-cause mortality: observations from the Framingham study over 35 years

Gene dose of apolipoprotein E type 4 allele and the risk of Alzheimer's disease in late onset families

Apolipoprotein E: high-avidity binding to beta-amyloid and increased frequency of type 4 allele in late-onset familial Alzheimer disease

APOE e4 genotype predicts severe COVID-19 in the UK Biobank community cohort

ApoE e4e4 genotype and mortality with COVID-19 in UK Biobank

Cardiometabolic traits, sepsis, and severe COVID-19: a Mendelian randomization investigation

Baseline Cardiometabolic Profiles and SARS-CoV-2 Risk in the UK Biobank

U-shaped relationship of HDL and risk of infectious disease: two prospective population-based cohort studies

Low serum level of high-density lipoprotein cholesterol is a poor prognostic factor for severe sepsis

Changes in HDL-associated apolipoproteins relate to mortality in human sepsis and correlate to monocyte and platelet activation

Is raising HDL a futile strategy for atheroprotection?

The role of HDL in innate immunity

HDL in innate and adaptive immunity

Emerging roles of HDL in immune function

Antiviral effects of apolipoprotein A-I and its synthetic amphipathic peptide analogs

Lipoproteins account for part of the broad non-specific antiviral activity of human serum

Apolipoprotein is responsible for neutralization of xenotropic type C virus by mouse serum

Neutralization of mouse xenotropic virus by lipoproteins involves binding to the virions

High-density lipoprotein loses its anti-inflammatory properties during acute influenza a infection

COVID-19-associated coagulopathy: An exploration of mechanisms

Lipoproteins as modulators of atherothrombosis: From endothelial function to primary and secondary coagulation

Causal inference for genetically determined levels of high-density lipoprotein cholesterol and risk of infectious disease

Evaluating the potential role of pleiotropy in Mendelian randomization studies

Lipid and metabolic syndrome traits in coronary artery disease: a Mendelian randomization study

Plasma HDL cholesterol and risk of myocardial infarction: a mendelian randomisation study

Apoprotein E as a lipid transport and signaling protein in the blood, liver, and artery wall

Apolipoprotein E: far more than a lipid transport protein

Apolipoprotein E -a multifunctional protein with implications in various pathologies as a result of its structural features

adjustment for only PC1-10, BMI, education, and smoking. Data are shown as ORs with 95%

All cases and controls were of white European ancestry. Cases were defined as symptomatic subjects who were positive for SARS-CoV-2 infection when tested in the hospital setting or whose cause of death was due to COVID-19. Unmatched hospital-based controls were defined as UK Biobank subjects who were evaluated for SARS-CoV-2 infection in inpatient or outpatient hospital settings and tested negative. Matched hospital-based controls were a subset of the unmatched controls who were matched to cases with respect to age, sex, obesity, hypertension

P-values for differences between cases and controls were derived from Mann-Whitney U tests for continuous variables or chi-square tests for dichotomous/categorical traits

Lipid-lowering medication use was available in 1,106 cases and 3,508 controls in the unmatched case-control set and in 711 cases and 1,429 controls in the matched case-control dataset

We gratefully acknowledge the UK Biobank Resource for providing access to their data under Application Number 33307. This work was supported, in part, by NIH Grants R01HL133169, R01ES025786, R01HL148110, R01HL144651, and R01DK117850. The sponsors had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript. 

HbA1c, hemoglobin A1c. Data are shown as medians and interquartile ranges (IQR) in cases and controls for whom serum biomarker levels were available. P-values for differences between cases and controls were derived from Mann-Whitney U tests.